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Purpose: Borderline prostatic lesions, with insufﬁcient histomorphologic features, to be deﬁnitely
diagnosed as prostatic adenocarcinoma (PCa) are often signed out as “atypical glands suspicious for
carcinoma” or atypical small acinar proliferation (ASAP). These ﬁndings that eventually warrant either
immunohistochemical (IHC) studies or a repeat biopsy, prove to be more burdensome to patients in
developing countries (such as the Philippines), where health care is not as progressive nor is it an utmost
priority. At the same time, in countries like the Philippines, there is a shortage of urological pathologists.
Methods: In this study, we compared the transrectal ultrasound-guided prostate (TRUS) biopsies signed
out by general surgical pathologists in St. Luke's Medical Center Quezon City from 2008e2010, and the
TRUS Biopsies primarily signed out by a urologic pathologist in both St. Luke's Medical Center Quezon
City and Global City from July 2013 to July 2014, and from September 2013 to July 2014, respectively.
Results: From 2008 to 2010, 30.6% (129 of 421) of the cases were signed out as atypical. Of these, 79
underwent IHC staining, 21 (26.6%) of which were eventually signed out as PCa. Compared to those
signed out in 2013 to 2014 by our genitourinary pathologist, only 16.6% (39 of 235) of the cases were
signed out as atypical. Of these, 16 underwent IHC staining, with 15 (93%) of them being deﬁnitively
diagnosed as PCa. Among the 21 cases wherein a repeat biopsy was recommended, only three followed
and two of these had ﬁndings of PCa on repeat biopsy. Looking at our 16.6% rate of atypicals and sub-
tracting those that were eventually established as PCa after IHCs, our atypicals would be down to 10%
(24/235) in 2013e2014 compared to 25.7% (108/421) in 2008e2010.
Conclusions: These results highlight the critical role a specialist has in the ﬁeld of urological pathology,
especially in developing countries. It is in the diagnosis of PCa in needle biopsies that a urological
pathologist impacts the use of an atypical diagnosis, by ensuring its judicious use. This ultimately
beneﬁts the patients, by lessening unwarranted expenses through the decreased dependence on IHC
staining and if necessary, a repeat biopsy.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Terms such as “atypical glands suspicious for carcinoma” and
“atypical small acinar prolilferation (ASAP)” are two of the more
common terms that have been used to describe those borderline
prostatic lesions that do not show any pathognomonic feature of
prostatic adenocarcinoma (PCa), but at the same time, reveal some
histomorphologic characteristics suggestive of PCa too worrisome
to be diagnosed as benign. The presence of an atypical ﬁnding
commonly necessitates either the use of immunohistochemicaluke's Medical Center, 279 E.
s.
ciﬁc Prostate Society, Published b(IHC) stains or a repeat biopsy, both of which require additional
ﬁnances. To patients in developing countries such as the
Philippines, however, these additional ﬁnances are a heavier
burden, as compared to patients in already developed countries.
In the current study, we aim to determine the impact of a
trained urological pathologist on our current rate of atypical di-
agnoses, now that he has been primarily evaluating our transrectal
ultrasound-guided prostate biopsy (TRUS) specimens for a 1 year
period.2. Materials and methods
We searched through the databases of St. Luke's Medical Center-
Quezon City (SLMC-QC), and St. Luke's Medical Center-Global Cityy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Data analysis.
Atypical cases Total P
þ 
GSP 129 292 421 0.0003
GUP 39 196 235
Atypical cases
w/IHC w/o IHC
GSP 79 50 129 0.013
GUP 16 23 39
Cases diagnosed after IHC
þ PCa  PCa
GSP 21 58 79 <0.001
GUP 15 1 16
Total after IHC
þ Atypical  Atypical
GSP 108 313 421 <0.001
GUP 24 211 235
Data are presented as n.
GUP, genitourinary pathologist; GSP, general surgical pathologist; IHC, immuno-
histochemical staining; PCa, prostatic adenocarcinoma.
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diagnosed by general surgical pathologists, were collected. These
cases from 2008 to 2010 were chosen because of a previous study
performed by the senior author (JSS) on the rate of “atypicals” in
their institution.1 These cases were then compared to those, which
were diagnosed by the senior author (a trained urological pathol-
ogist) at both SLMC-QC (from July 2013 to July 2014), and SLMC-GC
(from September 2013 to July 2014).
On both time frames, two pathologists have to agree on a
diagnosis of PCa or atypical in order for the ﬁnal diagnosis to be
released. Based on the ﬁnal diagnosis, cases were categorized
into three groups: Atypical glands present, Adenocarcinoma, and
Benign. The Atypical group was further subdivided to those that
required IHC staining and those that warranted a repeat biopsy.
A repeat biopsy was not an option during the 2008e2010 period.
The general pathologists who diagnosed an atypical ﬁnding were
not aware that such a suggestion could be a possible alternative
or could be the better recourse for the patient. IHC staining in
our institution, when requested by the pathologist, would
require the permission of the patient in order for it to proceed.
This would necessitate calling up the patient to make sure that
they are able and willing to pay for the said IHC stains. Only upon
the documented consent of the patient does the IHC staining
proceed.
The groups that underwent IHC staining and repeat biopsy were
recategorized to the three main groups of Atypical glands present,
Malignant, and Benign to get the ﬁnal percentages of each group.
From 2008 to 2010, IHC staining was performed using three
separate antibodies for P504s/alpha-methylacyl-CoA racemase
(AMACR), p63 and high-molecular weight cytokeratin (HMWCK).
With the exposure of the senior author to the more recent PIN4
cocktail staindwhich incorporates the three previously mentioned
stains (AMACR, p63 and HMWCK)dthe use of separate slides for
separate stains was now replaced. These ensured that the atypical
focus for IHC staining was still present in the tissue. Therefore,
those cases from 2013 to 2014 that required IHC staining made use
of the more recent PIN4 cocktail stain.
3. Results
A total of 421 TRUS biopsies were identiﬁed from January 2008
to December 2010, while a total of 235 TRUS biopsies were evalu-
ated by our urological pathologist at SLMC-QC and SLMC-GC from
July 2013 to July 2014, and from September 2013 to July 2014,
respectively (Table 1).
We were able to identify 41/137 (29.9%) atypical diagnoses in
2008, 46/150 (30.7%) in 2009 and 42/134 (31.3%) in 2010. In this 3-
year period, a total of 129/421 (30.6%) atypical diagnoses were
rendered in TRUS biopsies (see Table 2).
From these atypical cases from 2008 to 2010, 79 (61.2%) un-
derwent IHC staining and among them, 21 (26.6%) were ultimately
diagnosed as prostatic adenocarcinoma.
The senior author evaluated a total of 235 TRUS cases in 2013
and 2014. An atypical ﬁnding was rendered in 39/235 (16.6%) of
these TRUS cases. Among these cases from 2013 to 2014, 21/39Table 1
Data comparison between time frames.
Total TRUS Total ATYP ATYP which
underwent IHC
Cases diagnosed
as PCa after IHC
Total A
after I
2008e2010 421 129 (30.6) 79 21 (26.6) 108 (25
2013e2014 235 39 (16.6) 16 15 (93) 24 (10
Data are presented as n or n (%).
ATYP, atypical cases; IHC, immunohistochemical staining; PCa, prostatic adenocarcinom(53.8%) cases were advised to undergo staining. Of these, however,
only 16 (76.2%) pursued IHC. From the cases that did undergo IHC
staining, 15/16 (93.8%) cases were diagnosed as carcinoma, while
the one remaining case remained atypical with a patchy basal cell
staining pattern.
Unlike during the ﬁrst time frame (2008e2010), a patient with
an atypical diagnosis also had the option of having a repeat biopsy
instead of undergoing stains. Repeat biopsy was suggested in 18/39
(46.2%) cases. Among them, only three of 18 (16.7%) underwent a
repeat biopsy. Prostatic adenocarcinoma was identiﬁed in 66.7%
subsequent TRUS biopsies.4. Discussion
Prostate cancer remains one of the most common malignancies
diagnosed among men.2 A pathologist plays a critical role, not only
in the diagnosis, but also in whatever therapeutic modality a
prostate cancer patient will undergo.3 However, the diagnosis of
PCa can often be challenging, especially with the limited amount of
tissue that is submitted for a deﬁnite diagnosis. This is where the
use of an “atypical diagnosis” has tremendously aided pathologists.
With the use of an atypical diagnosis, a pathologist need not
commit to a benign or malignant diagnosis if he feels that the
features he is identifying are not satisfactory for either a benign or
malignant lesion.
An atypical diagnosis in TRUS biopsies, based on the literature, is
rendered in about 0.7e23.4% of cases, with an average of approxi-
mately 5%.3 An atypical diagnosis is usually given when the histo-






Cases diagnosed as PCa
after repeat biopsy (n)
.7) 0 0 0
) 18 3 2
a; TRUS, transrectal ultrasound-guided prostate biopsy.
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intraepithelial neoplasia (HGPIN) or various benign mimickers of
cancer. As previously mentioned, multiple terms have been used to
diagnose atypical glands. To those pathologists who do not
encounter enough TRUS specimens, the use of an atypical diagnosis
may be overused, even among those cases that are sometimes
overtly diagnosable as adenosis, atrophy (simple, partial, and
postatrophic), basal cell hyperplasia, and HGPINdthe more com-
mon benign mimickers of PCa.4e9
Based on our data from 2008 to 2010, our number of atypical
diagnosis, 30.6%, is beyond that of the range (0.7e23.4%) reported
in the literature.10 Most (79 cases) of these atypicals underwent
IHC staining. We compared these data with those TRUS biopsies,
which were diagnosed by the senior author, a urological pathol-
ogist. Our data showed that there was a signiﬁcant drop in the
number of cases signed out with an atypical diagnosis. From a rate
of 30.6% in 2008e2010 to 16.6% in 2013e2014dalmost half of
those reported in 2008e2010. Another important piece of data,
which we were able to show, was the percentage of PCa after IHC
staining. In 2008e2010, only 26.6% of those that underwent IHC
were ﬁnally diagnosed with PCa, while in 2013e2014, 93% were
established as PCa. We want to emphasize that our goal in this
study was not to minimize the value of an atypical diagnosis,
because as has been shown by Epstein and Herawi,10 the diagnosis
of “atypical” carried an average of 40.2% (median, 38.5%, range,
17e70%) increased risk of PCa on subsequent biopsy. What we do
aim for is to emphasize the critical role of a pathologist in the
diagnosis of PCa, more speciﬁcally the number of atypical cases
that are diagnosed. Based on our data, a specialist in the ﬁeld of
genitourinary pathology has a great impact in minimizing the
number of atypicals and reserving this atypical diagnosis to those
cases which are truly worthy of being labeled as such, especially
those which are really suspicious for prostatic adenocarcinoma or
other prostatic malignancies.
A specialist's presence is felt more in countries like the
Philippines, wherein most of the population lacks funds for the
most basic of necessities, even more, proper health care. Therefore
the use of IHC, though an indispensable tool in PCa diagnosis,11,12 is
usually beyond the ﬁnancial capabilities of the common Filipino
patient. That is why the percentage of cancer diagnoses, after IHC in
2008e2010, of 26.6% is a low number to justify the number of
atypicals as well as the request for IHCs. Thus the access, which our
patients have to our urological pathologist, has truly beneﬁted
them by decreasing the dependence on IHCs as well as lessening
those unwarranted atypical diagnoses. Furthermore, our ﬁnal
number of atypical diagnoses would be lower if we take into
consideration the fact that wewould have to ask for the permission
of a patient to proceed to IHC, unlike in developed countries, such
as the USA where patients have health insurance, which would
automatically cover the expenses for these stains. Looking at our
16.6% rate of atypicals and subtracting those which were eventually
established as PCa after IHC, our atypicals would be down to 10%
(24/235) versus 25.7% (108/421) in 2008e2010. From a ﬁnancial
standpoint of a patient, they would beneﬁt from a more deﬁnite
diagnosis instead of an unwarranted atypical ﬁnding because they
would not need further IHC staining or repeat biopsy, which will
eat up their ﬁnances that they may eventually have to utilize for
their treatment.5. Conclusion
In this day and agewheremost of the advances inmedicine have
been happening mostly at the molecular level, we hope that this
study will show that there is still a tremendous need for trained
specialists in various ﬁelds to practice in developing countries. We
feel that the diagnosis of PCa is just a small part of pathology, and
medicine for that matter, that needs the transfer of knowledge from
more developed countries.
The senior author (JSS) has been active in trying to educate his
fellow surgical pathologists in the hope of minimizing the unwar-
ranted use of an “atypical diagnosis”. He has also been trying to
convey to local urologists the tremendous impact that a needless
“atypical diagnosis” has on a patient.
The authors' goal in publishing this study is to be able to remind
our fellow pathologists about our tremendous role in the evalua-
tion of TRUS biopsies. We hope that through this study, our fellow
local surgical pathologists would aim to further educate themselves
to minimize their unwarranted “atypical diagnosis” rates. Another
study can also be donewherein, based on this present study, we can
analyze what are the most common reasons for unwarranted
atypical diagnosis among general pathologists.Conﬂicts of interest
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